Brandon Richland, MD Ozempic, known generically as semaglutide, is a medication approved for the management of type 2 diabetes
Survodutide was characterized in preclinical work as a molecule with meaningful activity at both receptors, engineered so that GLP-1 signaling constrains the glycemic risk of concurrent glucagon signaling
This matters especially because weight loss doesnt always tell the full story: significant weight loss, particularly with GLP-1 medications, can result in muscle loss, with 30 to 40% of the weight lost potentially coming from lean mass
What is the expected timeline for adjusting to taking semaglutide
Infections are more common with poor injection technique, reused needles, or inadequate site cleaning, and can occur whether the injection entered fat or muscle